Cargando…
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
Chimeric antigen receptor (CAR) T cells are a cancer immunotherapy of extremes. Unprecedentedly effective, but complex and costly to manufacture, they are not yet a therapeutic option for all who would benefit. This disparity has motivated worldwide efforts to simplify treatment. Among the proposed...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Gene & Cell Therapy
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263322/ https://www.ncbi.nlm.nih.gov/pubmed/35598048 http://dx.doi.org/10.1016/j.ymthe.2022.05.018 |